ArticleScientific reports2025
Traditional Chinese medicine-based therapeutics for Pediatric pneumonia-related acute lung injury and acute respiratory distress syndrome.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Role of Chinese Medicine in Treating Pediatric Respiratory Infections: A Comprehensive Review.Chinese journal of integrative medicine · 2026Review
- Integrated network pharmacology, transcriptomics and proteomics unveils the mechanisms of Forsythiae Fructus against acute lung injury.Die Naturwissenschaften · 2026Article
- A scoping review of the barriers and facilitators in the use of traditional, complementary, and integrative medicine: insights for health policy development.Journal of health, population, and nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Pediatric pneumonia remains a leading cause of morbidity and mortality among children worldwide, necessitating the exploration of novel therapeutic interventions. Traditional Chinese Medicine (TCM) offers a rich repository of natural compounds with potential therapeutic benefits. In this study, we explore the role of the TCM-derived compound ADHPE ([(1S,3S)-3-acetoxy-5-(3,4-dihydroxyphenyl)-1-[2-(3,4-dihydroxyphenyl)ethyl]pentyl]) as a stabilizer of 14-3-3σ and p65 complex in pediatric pneumonia through a comprehensive in silico approach. Using virtual screening and molecular docking, we screen the TCM drug library and assess the binding affinity of ADHPE to key protein targets implicated in the pathogenesis of pediatric pneumonia-associated acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). The stability and dynamics of the drug-target complexes are further evaluated through molecular dynamics (MD) simulations, providing insights into the interaction mechanisms at an atomic level. Additionally, we perform ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) analysis to predict the pharmacokinetic and safety profiles of ADHPE. Further, MM\GBSA, WaterMap, and Piper analyses were conducted to confirm the results. The findings from this study may pave the way for the development of effective TCM-based therapies for pediatric pneumonia, offering a promising alternative to current treatment modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.